HYML-122 for FLT3-mutated AML that came back or did not respond
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 2 trial studies HYML-122 in adults with acute myeloid leukemia (AML) that has either come back or did not respond to prior treatment. It targets tumors with an FLT3 mutation and may offer a new treatment option if your AML is resistant or relapsed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and can sign consent to join the study
- You have AML confirmed by blood/bone marrow testing, and it either did not respond to at least one chemotherapy cycle or it returned after remission
- Your AML has an FLT3 mutation found in your blood or bone marrow
- Your overall health is good enough to do daily activities (ECOG score 2 or less)
- Your doctor expects you can live at least 3 months
- If you can become pregnant, you must have a negative pregnancy test and use effective birth control during treatment and for 6 months after the last dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies HYML-122 together with cytarabine to treat adults with FLT3-positive acute myeloid leukemia (AML) that has come back or did not respond to prior treatment. It may help shrink the leukemia and improve blood-count recovery when standard treatments haven’t worked.
This trial tests a new treatment made from your own immune cells (CAR-T cells) that are designed to find and kill leukemia cells that have the FLT3 protein. It is for people with acute myeloid leukemia (AML) that has not responded to standard therapy or has returned after treatment.
This trial tests a new drug called HC-7366 for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. It aims to see if this drug is safe and helpful when standard options are no longer working.
This study tests a new experimental drug (NMS-03597812) for adults with AML that has not responded to or has returned after other treatments. The goal is to see if it is safe and if it can help control the leukemia.
This Phase 3 study compares HEC73543 versus standard “salvage” chemotherapy in adults with AML that has come back or did not respond after first treatment. It’s designed for people whose leukemia has an FLT3-ITD mutation and may help improve response and outcomes.
This trial tests an experimental oral medication called REM-422 for people with AML (a type of blood cancer) that has not responded to treatment or has come back, or for those with high-risk MDS. The goal is to see if it is safe and effective.
Hear when a new Relapsed or Refractory Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.